Eli Lilly to Acquire SiteOne Therapeutics for Non-Opioid Pain Treatment

Lilly and Company's acquisition of SiteOne Therapeutics, Inc. includes STC-004, a Phase 2 ready Nav1.8 inhibitor for pain treatment. The transaction could see SiteOne shareholders receive up to $1.0 billion in cash, subject to meeting specific milestones.